106 related articles for article (PubMed ID: 10656457)
1. Anti-HER2 antibody and heregulin suppress growth of HER2-overexpressing human breast cancer cells through different mechanisms.
Le XF; McWatters A; Wiener J; Wu JY; Mills GB; Bast RC
Clin Cancer Res; 2000 Jan; 6(1):260-70. PubMed ID: 10656457
[TBL] [Abstract][Full Text] [Related]
2. Differential signaling by an anti-p185(HER2) antibody and heregulin.
Le XF; Vadlamudi R; McWatters A; Bae DS; Mills GB; Kumar R; Bast RC
Cancer Res; 2000 Jul; 60(13):3522-31. PubMed ID: 10910064
[TBL] [Abstract][Full Text] [Related]
3. Heregulin and agonistic anti-p185(c-erbB2) antibodies inhibit proliferation but increase invasiveness of breast cancer cells that overexpress p185(c-erbB2): increased invasiveness may contribute to poor prognosis.
Xu FJ; Stack S; Boyer C; O'Briant K; Whitaker R; Mills GB; Yu YH; Bast RC
Clin Cancer Res; 1997 Sep; 3(9):1629-34. PubMed ID: 9815853
[TBL] [Abstract][Full Text] [Related]
4. Augmentation of a humanized anti-HER2 mAb 4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor mAb C225.
Ye D; Mendelsohn J; Fan Z
Oncogene; 1999 Jan; 18(3):731-8. PubMed ID: 9989823
[TBL] [Abstract][Full Text] [Related]
5. The role of cyclin-dependent kinase inhibitor p27Kip1 in anti-HER2 antibody-induced G1 cell cycle arrest and tumor growth inhibition.
Le XF; Claret FX; Lammayot A; Tian L; Deshpande D; LaPushin R; Tari AM; Bast RC
J Biol Chem; 2003 Jun; 278(26):23441-50. PubMed ID: 12700233
[TBL] [Abstract][Full Text] [Related]
6. Enhancement of the p27Kip1-mediated antiproliferative effect of trastuzumab (Herceptin) on HER2-overexpressing tumor cells.
Marches R; Uhr JW
Int J Cancer; 2004 Nov; 112(3):492-501. PubMed ID: 15382077
[TBL] [Abstract][Full Text] [Related]
7. Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene.
Pietras RJ; Poen JC; Gallardo D; Wongvipat PN; Lee HJ; Slamon DJ
Cancer Res; 1999 Mar; 59(6):1347-55. PubMed ID: 10096569
[TBL] [Abstract][Full Text] [Related]
8. HER2-targeting antibodies modulate the cyclin-dependent kinase inhibitor p27Kip1 via multiple signaling pathways.
Le XF; Pruefer F; Bast RC
Cell Cycle; 2005 Jan; 4(1):87-95. PubMed ID: 15611642
[TBL] [Abstract][Full Text] [Related]
9. Involvement of p27KIP1 in G1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody.
Wu X; Rubin M; Fan Z; DeBlasio T; Soos T; Koff A; Mendelsohn J
Oncogene; 1996 Apr; 12(7):1397-403. PubMed ID: 8622855
[TBL] [Abstract][Full Text] [Related]
10. Antibody targeting of HER2/HER3 signaling overcomes heregulin-induced resistance to PI3K inhibition in prostate cancer.
Poovassery JS; Kang JC; Kim D; Ober RJ; Ward ES
Int J Cancer; 2015 Jul; 137(2):267-77. PubMed ID: 25471734
[TBL] [Abstract][Full Text] [Related]
11. Critical role for p27Kip1 in cell cycle arrest after androgen depletion in mouse mammary carcinoma cells (SC-3).
Menjo M; Kaneko Y; Ogata E; Ikeda K; Nakanishi M
Oncogene; 1998 Nov; 17(20):2619-27. PubMed ID: 9840925
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of the melanoma cell cycle and regulation at the G1/S transition by 12-O-tetradecanoylphorbol-13-acetate (TPA) by modulation of CDK2 activity.
Coppock DL; Buffolino P; Kopman C; Nathanson L
Exp Cell Res; 1995 Nov; 221(1):92-102. PubMed ID: 7589260
[TBL] [Abstract][Full Text] [Related]
13. Heregulin-dependent delay in mitotic progression requires HER4 and BRCA1.
Muraoka-Cook RS; Caskey LS; Sandahl MA; Hunter DM; Husted C; Strunk KE; Sartor CI; Rearick WA; McCall W; Sgagias MK; Cowan KH; Earp HS
Mol Cell Biol; 2006 Sep; 26(17):6412-24. PubMed ID: 16914727
[TBL] [Abstract][Full Text] [Related]
14. Cyclin E-cdk2 activation is associated with cell cycle arrest and inhibition of DNA replication induced by the thymidylate synthase inhibitor Tomudex.
Yin MB; Guo B; Panadero A; Frank C; Wrzosek C; Slocum HK; Rustum YM
Exp Cell Res; 1999 Feb; 247(1):189-99. PubMed ID: 10047461
[TBL] [Abstract][Full Text] [Related]
15. Induction of sensitivity to doxorubicin and etoposide by transfection of MCF-7 breast cancer cells with heregulin beta-2.
Harris LN; Yang L; Tang C; Yang D; Lupu R
Clin Cancer Res; 1998 Apr; 4(4):1005-12. PubMed ID: 9563896
[TBL] [Abstract][Full Text] [Related]
16. Heregulin activation of extracellular acidification in mammary carcinoma cells is associated with expression of HER2 and HER3.
Chan SD; Antoniucci DM; Fok KS; Alajoki ML; Harkins RN; Thompson SA; Wada HG
J Biol Chem; 1995 Sep; 270(38):22608-13. PubMed ID: 7673253
[TBL] [Abstract][Full Text] [Related]
17. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells.
Carlson BA; Dubay MM; Sausville EA; Brizuela L; Worland PJ
Cancer Res; 1996 Jul; 56(13):2973-8. PubMed ID: 8674031
[TBL] [Abstract][Full Text] [Related]
18. Interaction of retinoblastoma protein and D cyclins during cell-growth inhibition by hexamethylenebisacetamide in TM2H mouse epithelial cells.
Said TK; Medina D
Mol Carcinog; 1998 Jun; 22(2):128-43. PubMed ID: 9655257
[TBL] [Abstract][Full Text] [Related]
19. Neu differentiation factor (Heregulin) activates a p53-dependent pathway in cancer cells.
Bacus SS; Yarden Y; Oren M; Chin DM; Lyass L; Zelnick CR; Kazarov A; Toyofuku W; Gray-Bablin J; Beerli RR; Hynes NE; Nikiforov M; Haffner R; Gudkov A; Keyomarsi K
Oncogene; 1996 Jun; 12(12):2535-47. PubMed ID: 8700512
[TBL] [Abstract][Full Text] [Related]
20. The role of p27Kip1 in gamma interferon-mediated growth arrest of mammary epithelial cells and related defects in mammary carcinoma cells.
Harvat BL; Seth P; Jetten AM
Oncogene; 1997 May; 14(17):2111-22. PubMed ID: 9160891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]